patients and found that GLP-1 agonists (like semaglutide, related to tirzepatide) were associated with a significantly higher risk of developing gastroparesis-like symptoms or confirmed gastroparesis
The 'weight loss jab': GLP-1 and GIP medications These medications are known by many forms, depending on the country and licences
Is PT-141 nasal spray for men, women, or both
This includes physician offices, outpatient clinics, and hospital outpatient departments
The evidence base regarding GLP-1 receptor agonists in patients with inflammatory bowel disease, including Crohn's disease, remains limited but is an area of growing research interest
Let the water trickle down the side of the glass